Gnetol

Research use only, not for human use.

Gnetol competitivity inhibits butyrylcholinesterase (IC50: 1.3 uM). Gnetol has a strong inhibitory effect on murine tyrosinase activity.

Gnetol competitivity inhibits butyrylcholinesterase (IC50: 1.3 uM). Gnetol has a strong inhibitory effect on murine tyrosinase activity. Gnetol significantly suppresses melanin biosynthesis in murine B16 melanoma cells. It is active in the inhibition of arachidonic acid (AA)-induced platelet aggregation.

The antiproliferative activities of Gnetol are tested in HCT-116, Hep-G2, MDA-MB-231, and PC-3 cell lines by measuring cell viability after treatment with 4.1 μM, 40.9 μM, 204.7 μM, 409.4 μM, and 1023.6 μM. Gnetol shows concentration-dependent reductions in cell viability in cancer cell lines with greatest activity in colorectal cancer.Gnetol at 200 μg/mL significantly offers the highest protection of 54.3% against the toxicant. A lower dose of Gnetol (50 μg/mL) also shields the cell line from the toxic effects of CCl4. The ligand molecule TGF-β and PPARα protein show that Gnetol has the binding affinity of 7.0 and 8.4, respectively.

Male Sprague-Dawley rats were cannulated and dosed either intravenously with Gnetol (10?μg/kg) or orally (100?mg/kg). After oral and intravenous administration, Gnetol is detected in both serum and urine as the parent compound and as a glucuronidated metabolite. The bioavailability of Gnetol is determined to be 6%. Gnetol is rapidly glucuronidated and is excreted in urine and via nonrenal routes.Pretreatment of Male NIH Swiss mice (20-35 g) with Gnetol (50mg/kg, SC) is able to increase the latency period to response in analgesia models.

——

Metabolic Enzyme/Protease

P450

BChE| Tyrosinase

——

——

86361-55-9

244.24

C14H12O4

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (409.43 mM)

C1=CC(=C(C(=C1)O)/C=C/C2=CC(=CC(=C2)O)O)O

——

(-20℃)

With Ice Pack

≥ 2 years